|
|
|
|
|
|
|
|
|
|
|
|
|
|
Previous: 13A COMMERCIAL MORTGAGE SECURITIES FUND INC, N-30D, 1998-12-30 |
Next: AMPACE CORP, 8-K, 1998-12-30 |
U.S. Securities and Exchange Commission
Washington, D.C. 20549
FORM 10-QSB/A
(Amendment No. 1)
(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934.
For the quarterly period ended JUNE 30, 1998
----------------
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from __________ to __________
Commission File Number 0-25828
ELECTROPHARMACOLOGY, INC.
---------------------------------------------------------------
Exact name of small business issuer as specified in its charter
DELAWARE 95-4315412
--------------------------------- -------------------
(State or other jurisdiction (IRS Employer
of incorporation or organization) Identification No.)
1109 N.W. 13th STREET, GAINESVILLE, FL 32601
--------------------------------------------------------
(Address of principal executive offices)
(352) 367-9088
--------------
(Issuer's telephone number)
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes X No
--- ---
State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:
Number of Shares Outstanding
Class On June 30, 1998
----- -----------------
Common Stock, $.01 par value 4,132,493
---------
Transitional Small Business Disclosure Format:
Yes No X
--- ---
<PAGE>
ELECTROPHARMACOLOGY, INC.
The following information is hereby amended in its entirety:
1. The Statements of Operations for the three months ended June 30, 1998 and
1997, contained in Item 1.
1
<PAGE>
ELECTROPHARMACOLOGY, INC.
Statments of Operations
(UNAUDITED)
<TABLE>
<CAPTION>
For the three months ended
June 30,
------------------------------------------
1998 1997
---- ----
<S> <C> <C>
Revenue:
Rentals $ 143,445 $ 566,923
Sales 42,000 143,000
----------- -----------
Total Revenue 185,445 709,923
Operating expenses:
Cost of revenue 67,064 114,275
Selling, general and administrative 419,874 981,235
Research and development 13,863 73,757
----------- -----------
Total operating expenses 500,801 1,169,267
----------- -----------
Loss from operations (315,356) (459,344)
Other income (expense)
Interest expenses (20,939) (4,941)
Interest and other income 2,561 3,327
----------- -----------
Total other income (expense) (18,378) (1,614)
----------- -----------
Net loss $ (333,734) $ (460,958)
=========== ===========
Net loss per share - basic and diluted $ (0.08) $ (0.13)
=========== ===========
Weighted average number of common shares 4,132,493 3,671,869
outstanding - basic and diluted =========== ===========
</TABLE>
See accompanying notes to financial statements.
2
<PAGE>
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
ELECTROPHARMACOLOGY, INC.
Registrant
Dated: December 30, 1998 /s/ DR. ARUP SEN
-------------------------------------
Dr. Arup Sen
Chief Executive Officer
/s/ DAVID SALOFF
-------------------------------------
David Saloff
Chief Financial Officer and Executive
VicePresident - Marketing
3
|
|